Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8264799 | 0.92 | CDK2 (0.47) | CDK2PTGS2HRH3NPC1POLB | |
| SCHEMBL12845448 | 0.87 | HRH3 (0.50) | CDK2PTGS2HRH3POLBPAK4 | |
| SCHEMBL12845611 | 0.87 | HRH3 (0.49) | CDK2PTGS2HRH3POLBPAK4 | |
| SCHEMBL12845701 | 0.87 | CDK2 (0.48) | CDK2PTGS2HRH3NPC1POLB | |
| SCHEMBL12845641 | 0.87 | HRH3 (0.46) | CDK2PTGS2HRH3PAK4 | |
| SCHEMBL12845428 | 0.86 | HRH3 (0.44) | CDK2PTGS2HRH3POLBPTGS1 | |
| SCHEMBL12845350 | 0.85 | CDK2 (0.47) | CDK2PTGS2HRH3NPC1POLB | |
| SCHEMBL12845461 | 0.85 | HRH3 (0.48) | CDK2PTGS2HRH3POLBPAK4 | |
| SCHEMBL12845458 | 0.85 | HRH3 (0.47) | CDK2PTGS2HRH3POLBPTGS1 | |
| SCHEMBL13037147 | 0.84 | PTGS2 (0.50) | CDK2PTGS2HRH3PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404683-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2013-03-26 | — | — | US | disclosed |
| US-20110053937-A1 | Inhibitors of the Interaction Between MDM2 and P53 | LACRAMPE JEAN FERNAND ARMAND | 2011-03-03 | — | — | US | disclosed |
| US-7834016-B2 | Inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-16 | — | — | US | disclosed |
| US-7834016-B2 | Inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-16 | — | — | US | disclosed |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053937-A1 | Inhibitors of the Interaction Between MDM2 and P53 | TP53, MDM2, TP53BP1 | CDK2 36/4885PTGS2 3159/4885HRH3 3525/4885 |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | TP53, MDM2, TP53BP1 | CDK2 36/4885PTGS2 3159/4885HRH3 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.